ORIC Corp - ORIC Company Short-Term Debt

ORIC Pharmaceuticals, Inc. (ORIC) - corporate logo

ORIC Pharmaceuticals brings together distinguished biologists striving to create breakthrough oncology therapies backed by substantial investments. This chart, featuring the 0.00 metric, highlights key drivers: the success of clinical trials for new inhibitors and potential acquisition by industry behemoths such as Pfizer. The company currently relies on support from institutional investors while its primary drug candidates undergo testing.

ORIC: oricpharma.com Short-Term Debt 07/04/2022 - 10/28/2026

ORIC (ORIC Corp): analytical breakdowns and indicator data

- price and consensus price forecast:
Price Chart ORIC Pharmaceuticals, Inc.|ORIC - Average Forecast Price
- market capitalization data:
Market Value ORIC Pharmaceuticals, Inc.|ORIC - Total Company Value
- book capitalization data:
Net Assets per Single Share ORIC Pharmaceuticals|ORIC - Total Stockholders' Equity|Market Capitalization to Book Value Ratio oricpharma.com|ORIC - Company Balance Sheet Assets
- debt and liquidity data:
Total Debt to Equity Ratio ORIC Pharmaceuticals|ORIC - Long-Term Liabilities to Capital|Short-Term Debt to Equity Ratio ORIC Pharmaceuticals|ORIC - Aggregate Debt Obligations|Debt to Book Value ORIC Pharmaceuticals, Inc.|ORIC - Amount of Long-Term Liabilities|Company Short-Term Debts ORIC Pharmaceuticals
Initial company analysis:ORIC (ORIC Pharmaceuticals, Inc.)
Finished products of oricpharma.com

Assessing asset quality requires analyzing liquidity through the lens of current liabilities. This indicator measures the volume of debt maturing within one year, determining the business's immediate solvency. The price action on the short-term debt chart reflects the balance between financial stability and expansion rates. For ORIC Pharmaceuticals (ORIC), this is a critical marker of the ability to fund the development of targeted therapy while maintaining its scientific reputation.

Competitors of ORIC Pharmaceuticals (ORIC)

GMAB (Genmab) - Company Short-Term Debt|EXEL: Short-Term Debt|Nuvalent Corp (NUVL) - Company Short-Term Debt|KYMR (Kymera Corp) - Company Short-Term Debt|Company Short-Term Debt IDYA (IDEAYA Biosciences)|Short-Term Debt enliventherapeutics.com|RLAY: Company Short-Term Debts|Short-Term Indebtedness Nurix Therapeutics Inc NRIX|TYRA: Company Current Liabilities|VSTM - Short-Term Debt|Company Current Liabilities Monte Rosa Therapeutics (GLUE)|cullinanoncology.com (CGEM) - Company Short-Term Loans and Borrowings|IMRX - Company Current Liabilities|C4 Therapeutics Inc (CCCC) - Amount of Current Liabilities|BDTX (Black Diamond Therapeutics Inc.) - Company Short-Term Debts|Company Short-Term Debts RPTX|PMV Pharmaceuticals (PMVP) - Company Short-Term Debt|Company Short-Term Loans and Borrowings karyopharm.com (KPTI)|PPCB (Propanc Biopharma) - Company Short-Term Debts|Short-Term Indebtedness Bio Green Med Solution Inc. BGMS|AADI (Aadi Bio) - Company Short-Term Debts|Aileron Therapeutics (ALRN) - Short-Term Debt|BPMC - Company Current Liabilities|GlycoMimetics (GLYC) - Amount of Current Liabilities|Company Short-Term Debts SWTX (SpringWorks Therapeutics, Inc.)